Piper Sandler analyst Matthew O'Brien maintains $TransMedics (TMDX.US)$ with a buy rating, and maintains the target price at $180.
According to TipRanks data, the analyst has a success rate of 49.5% and a total average return of 4.6% over the past year.
Furthermore, according to the comprehensive report, the opinions of $TransMedics (TMDX.US)$'s main analysts recently are as follows:
TransMedics' third-quarter results fell short of expectations, and while the management has upheld its guidance for FY24, it suggests a broad spectrum of growth possibilities for the fourth quarter. Despite a sequential dip in transplant volumes across all three organ categories, the company maintains that it has not conceded any market share during the quarter. Analysts perceive the company as a dominant player in a market that remains largely untapped.
While there was an anticipation of a more subdued upside in Q3 for TransMedics, the actual performance shortfall was unexpected. Despite this, the company achieved significant growth of +64% and maintained its guidance for FY24. The challenges faced are seen as temporary and are not a result of market share loss or pricing pressure related to OCS disposables.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
派杰投资分析师Matthew O'Brien维持$TransMedics (TMDX.US)$买入评级，维持目标价180美元。
根据TipRanks数据显示，该分析师近一年总胜率为49.5%，总平均回报率为4.6%。
此外，综合报道，$TransMedics (TMDX.US)$近期主要分析师观点如下：
TransMedics的第三季度业绩低于预期，尽管管理层维持了对24财年的指导，但它表明第四季度存在广泛的增长可能性。尽管所有三个器官类别的移植量连续下降，但该公司坚称本季度没有让出任何市场份额。分析师认为，该公司在仍未开发的市场中占据主导地位。
尽管预计TransMedics在第三季度的上行空间将更加疲软，但实际的业绩不足却出乎意料。尽管如此，该公司还是实现了+64％的显著增长，并维持了24财年的预期。面临的挑战被视为暂时性的，不是市场份额损失或与OCS一次性用品相关的定价压力造成的。
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
